Company news

Tiziana Life Sciences Ltd news in 2024

Tiziana Life Sciences Ltd's news releases, calls and decks from 2024, newest first.

View company

Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab

December 16, 2024

Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers

December 3, 2024

Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association

November 18, 2024

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

October 31, 2024

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million

October 29, 2024

Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study

October 29, 2024

Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease

September 18, 2024

Tiziana Life Sciences Appoints New Chief Executive Officer

August 18, 2024

Tiziana Life Sciences Granted FDA Fast Track Designation

July 23, 2024

Tiziana Receives $3.4 Million in Non-Dilutive Funding

June 27, 2024

Tiziana Life Sciences adds to treasury with $3.4 million in non-dilutive funding

June 27, 2024

Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab

June 25, 2024

FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis

June 10, 2024

Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab

June 5, 2024

Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab

June 3, 2024

Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab

May 12, 2024

Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab

April 24, 2024

Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program

April 22, 2024

Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program

April 21, 2024

Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®

April 18, 2024

Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

April 10, 2024

Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease

March 4, 2024

Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients

January 7, 2024

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

January 4, 2024

Decks in 2024